MAP2K7 and melanoma: Given the rapidly evolving combination treatment landscape, future studies using the KRAS G13D/BRAF V600E isogenic model of drug-resistant melanoma described here should focus on combination PD-L1 and BRAF/MEK inhibitor treatment.